Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 31c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of ($1.75), $0.31 worse than the analyst estimate of ($1.44). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $21.74 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
• Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan